Pediatric Oncology
Note: This page is educational and reflects the state of the literature in 2025. It does not replace medical advice.
TL;DR
Childhood cancer is rare but high-impact: about 15 000 children and adolescents per year are diagnosed in the US, with >85 % surviving five years thanks to multidisciplinary protocols.In Brazil, INCA estimates ~8 000 new pediatric cancer cases per year. The biology, treatment principles, and ethical framework differ meaningfully from adult oncology — and survivorship is now a defining concern: by age 45, ~95 % of survivors will have developed a significant treatment-related health problem. Sources: [1]
1. Why pediatric oncology is its own field
Pediatric tumors differ from adult cancers in several key ways:
- Different histologies dominate. Acute lymphoblastic leukemia (ALL), CNS tumors, lymphomas, neuroblastoma, Wilms tumor, soft-tissue and bone sarcomas, retinoblastoma — embryonal and developmental in origin, not the carcinomas that dominate adult oncology.
- Lower mutation burden. Pediatric tumors typically have far fewer somatic mutations than adult tumors; drivers are often single fusions or recurrent events (e.g., MYCN amplification in neuroblastoma, EWSR1-FLI1 in Ewing sarcoma, BRAF fusions in pediatric low-grade glioma).
- Higher chemo-sensitivity. Many pediatric cancers respond strongly to multi-agent chemotherapy that is too toxic for older adults.
- Developmental physiology. Drug metabolism, growth, organ maturation, and behavior all change therapy choices and toxicity windows.
- Cooperative-group framework. Most patients are treated on or after a Children's Oncology Group (COG) / SIOP / GBOP protocol — a very different evidence base than adult community oncology.
2. Common pediatric cancers
| Cancer | Notes |
|---|---|
| Acute lymphoblastic leukemia (ALL) | Most common; ~85–90 % cure rate in pediatric B-ALL with risk-adapted therapy; CD19 CAR-T for relapsed/refractory cases |
| CNS tumors | Now the leading cause of cancer death in childhood; gliomas (low- and high-grade), medulloblastoma, ependymoma |
| Lymphomas | Hodgkin and non-Hodgkin; high cure rates with chemo ± radiation |
| Neuroblastoma | Sympathetic nervous system; risk-stratified by MYCN status, age, stage |
| Wilms tumor (nephroblastoma) | Excellent prognosis with surgery + chemo ± radiation |
| Sarcomas | Soft-tissue (rhabdomyosarcoma) and bone (osteosarcoma, Ewing) |
| Retinoblastoma | Eye tumor; germline RB1 mutation in heritable form |
| Hepatoblastoma | Liver; surgical resection central |
| Germ cell tumors | Variable; chemosensitive |
Pediatric low-grade glioma (pLGG) is the most common CNS tumor in children — increasingly conceptualized as a chronic disease with focus on functional outcomes and targeted therapy (BRAF/MEK inhibitors for MAPK-pathway alterations). Sources: [2]
3. Treatment principles
- Risk-adapted therapy. Stratification by stage, biology, and response — escalating intensity for high-risk, de-escalating for low-risk to reduce late effects.
- Multimodal protocols. Surgery + chemotherapy + radiation + (increasingly) targeted/immunotherapy.
- Clinical trial enrollment. A historically high proportion of pediatric oncology patients are enrolled in cooperative-group trials, which is a major reason cure rates have improved.
- Multidisciplinary team. Pediatric oncologist, surgeon, radiation oncologist, pathologist, pharmacist, nurse, social worker, child-life specialist, school liaison, psychologist, palliative care.
- Family-centered care. The "patient" is the family — communication, decision-making, and support involve parents, siblings, and the child appropriate to age.
4. Late effects and survivorship — the new mainstream
With cure as the expected outcome for most pediatric cancers, the focus has shifted to what happens decades later. The Childhood Cancer Survivor Study (CCSS) and similar cohorts have shown: Sources: [1]
- ~95 % of survivors have a significant chronic condition by age 45.
- The most common severe / life-threatening late effects:
- Endocrine (~44 %) — hypothyroidism, growth hormone deficiency, infertility.
- Subsequent neoplasms (~7 %) — radiation-induced thyroid, breast, sarcomas.
- Cardiovascular (~5 %) — anthracycline-induced cardiomyopathy, radiation-related coronary disease.
- Highest-risk groups: brain tumor survivors who received cranial radiation (~70 % serious health problems) and allogeneic HSCT recipients (~60 %).
- Lowest-risk: solid tumors treated with surgery alone or minimal chemo (similar to general population).
Long-term follow-up is now standard of care in major pediatric oncology centers. Brazilian centers have developed survivorship clinics, but coverage and access remain uneven across the country.
5. Ethical and regulatory specifics
Pediatric research has stricter rules than adult research:
- Assent + parental consent. The child gives age-appropriate assent; the parent or legal guardian gives consent. Both are required when the child is capable of assenting.
- Risk thresholds. US Common Rule §50.50–55 categorizes pediatric research by risk level and requires IRB justification for each.
- Therapeutic vs. non-therapeutic. Greater scrutiny for non-therapeutic procedures.
- Vulnerable population. Pediatric patients are categorically vulnerable; protocols must justify minimization of risk and procedures.
- Pediatric-specific endpoints and toxicity grading (CTCAE-Ped).
- Long follow-up obligations for late effects.
In Brazil, CONEP/Plataforma Brasil review pediatric protocols with extra scrutiny; the Lei 14.874/2024 reinforces pediatric protections. See Regulatory & ethics.
6. Brazilian context
- INCA estimates ~8 000 new pediatric cancer cases per year in Brazil; cure rates roughly 65–70 % overall, with significant regional variation.
- GRAACC (São Paulo) is the largest dedicated pediatric oncology center; GBOP (Brazilian Pediatric Oncology Group) coordinates multicenter cooperative trials.
- Hospital de Câncer de Barretos, Hospital A.C. Camargo, Hospital Pequeno Príncipe (Curitiba), Boldrini (Campinas), Hospital Israelita Albert Einstein, and several public-academic services host major pediatric programs.
- Lei dos 60 dias (12.732/2012) and SUS oncology pathways apply.
- Childhood cancer awareness campaigns and school-leave protections have expanded since the 2000s.
- A persistent challenge: late presentation — diagnostic delay is a major driver of poorer outcomes in some regions.
7. Where technologists can contribute
- Survivorship registries and risk calculators — automate late-effect surveillance reminders by treatment exposure.
- Trial-matching tools — pediatric trials are scarce; matching is high-stakes.
- Family communication tools — multilingual, age-appropriate explainers and decision aids.
- Imaging analysis with pediatric-specific datasets — adult-trained models often fail on pediatric anatomy.
- Wearables and ePROs for symptom tracking in long-running treatment.
- Diagnostic delay — community-level alerting and referral pathways for nonspecific pediatric symptoms.
For broader background: Clinical trials, Regulatory & ethics, Psycho-oncology.
See also
References
- Bhatia S, Tonorezos ES, Landier W. Clinical Care for People Who Survive Childhood Cancer: A Review. JAMA 2023;330:1175-1186. PMID 37750876. https://doi.org/10.1001/jama.2023.16875
- Fangusaro J, Jones DT, Packer RJ, et al. Pediatric low-grade glioma: State-of-the-art and ongoing challenges. Neuro Oncol 2024;26:25-37. PMID 37944912. https://doi.org/10.1093/neuonc/noad195
- U.S. National Cancer Institute. Childhood cancers. https://www.cancer.gov/types/childhood-cancers
- American Cancer Society. Cancers in Children. https://www.cancer.org/cancer.html
- Cleveland Clinic. Childhood cancers (overview). https://my.clevelandclinic.org/health/diseases/12194-cancer
- Instituto Nacional de Câncer (INCA). Estimativa: incidência de câncer no Brasil — câncer infantojuvenil. https://www.inca.gov.br/
- GRAACC — Grupo de Apoio ao Adolescente e à Criança com Câncer. https://www.graacc.org.br/
- A.C. Camargo Cancer Center. https://accamargo.org.br
- Fundação do Câncer (Brasil). https://www.cancer.org.br/
- Ministério da Saúde / BVS. ABC do câncer. https://bvsms.saude.gov.br/bvs/publicacoes/abc_do_cancer.pdf